Leukemia: A Review of Data from the ASCO and EHA 2023 Meetings

EP. 1: Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

ByElias Jabbour, MD,James M. Foran, MD,Hannah Choe, MD,Jorge Cortes, MD

August 31st 2023

Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

EP. 2: Acute Lymphoblastic Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

ByElias Jabbour, MD,James M. Foran, MD,Hannah Choe, MD,Jorge Cortes, MD

August 31st 2023

Shared insight from key opinion leaders on clinical trial data in acute lymphoblastic leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

EP. 3: Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

ByElias Jabbour, MD,James M. Foran, MD,Hannah Choe, MD,Jorge Cortes, MD

August 31st 2023

Following the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

Harold P. Freeman, MD, Pioneer of Patient Navigation and Cancer Disparities Research, Dies at 93